Dr. Stella Xu is Managing Director of Quan Capital, a life science venture fund with deep expertise and broad experiences in cross-border value creation and global investments. Prior to Quan, Stella was Corporate VP/Site Head of Roche R&D Center China and a core member of the global management team of Roche’s Immunology, Inflammation & Infectious Diseases. From 2012-2017, she led the fully integrated team of ~200 scientists to deliver an innovative pipeline from Discovery to global clinical development. She also had extensive global business development experience with Roche Partnering. Stella joined Roche from McKinsey US and worked in biotech R&D earlier in her career. Stella received her Ph.D. in Immunology from Northwestern University, and B.S. in Biophysics from Peking University. Stella currently serves on the Board of NextCure (Nasdaq: NXTC), Centrexion Therapeutics, Tempest Therapeutics, Walking Fish Therapeutics, Zidan Medical and Design Therapeutics. She was a board member of ARMO BioSciences (Nasdaq: ARMO).